XENOTHERA

French biotech that develops innovative treatments such as #XAV19 against #covid19 🧪🔬 #biotechnology #immunology

[XENOTHERA @xenothera]

📣 #Lymphome #Traitement | Nous annonçons le recrutement du 1er patient pour notre essai PALT1, visant à traiter le lymphome T périphérique (#PTCL), et sa désignation de médicament orphelin (ODD) accordée par l'EMA.

🔍 Plus d'infos dans notre communiqué : https://t.co/QTJ5zNM7xx

[XENOTHERA @xenothera]

📣 #Lymphoma #Treatment | We announce the recruitment of the first patient for our PALT1 trial, aimed at treating Peripheral T-Cell Lymphoma (#PTCL), and its Orphan Drug Designation (ODD) granted by the EMA.

🔍 More details in our press release: https://t.co/wN57NlRRt1

[XENOTHERA @xenothera]

🔬 #CancerResearch | A recent article published by Cancer Biology & Medicine, led by researchers from Guangdong Pharmaceutical University, explores significant advancements in immune checkpoint inhibitors (ICIs) ⬇️

#Immunotherapy #CancerTreatment
https://t.co/BeBgYRCvuG

[XENOTHERA @xenothera]

Each dose step-up brings us closer to the supposed therapeutic dose.

#Oncology #Innovation #Health #XON7 #ClinicalTrial #Biotech #CancerTreatment

[XENOTHERA @xenothera]

📣 #Cancer: start of the 4th cohort of the FIPO trial (ascending phase)

✅ The Scientific Advisory Board of the FIPO clinical trial has given the go-ahead for the start of the fourth dose of the ascending phase, considering the safety of the previous dose.

[XENOTHERA @xenothera]

The aim of this initial (ascending) phase is to ensure the safety of the product and estimate its benefit/risk ratio. XON7 is offered to patients suffering from solid tumors of all types who have failed on currently available treatments.

[XENOTHERA @xenothera]

🌐 #XENOSPHERE: ensuring low immunogenicity with our GH-pAb platform 🧬

➡️ To find out more about our mission and technology, visit our website: https://t.co/yuETFqblVh

#Innovation #Biotech #Healthcare #Immunology #LowImmunogenicity #PolyclonalAntibodies #GHpAb

[XENOTHERA @xenothera]

🔬 #Immunotherapy | This insightful article by @CR_UK explores how tracking the co-evolution of tumors and the immune system can enhance cancer treatments.

https://t.co/DAjaa8sFV5

[XENOTHERA @xenothera]

🧬 #PolyclonalAntibodies | This article about @gigageninc highlights the incredible potential of polyclonal antibodies in treating various diseases. At XENOTHERA, we are convinced and fully aligned with this innovative approach.

Via @DrugTargetRev 👇
https://t.co/r5G0IuxrVU

[XENOTHERA @xenothera]

🔬 #Cancer #immunotherapy resistance: a recent study published in @ScienceAdvances identifies a unique approach to overcoming resistance to cancer immunotherapy.

🔍 Read the full study for more details 🔽
https://t.co/KFfYlc9ZOi

#CancerResearch #Immunotherapy #Oncology

[XENOTHERA @xenothera]

🦠🔬 #Covid #Treatment | Clinical efficacy of our anti-COVID antibody, XAV-19, published in Frontiers in Immunology : https://t.co/wOvPC5f7QB

🔍 More info in our press release: https://t.co/1tbzc0k1zN

[XENOTHERA @xenothera]

🦠🔬 #Covid #Traitement | Publication de l’efficacité clinique de notre anticorps anti-COVID, le XAV-19, dans Frontiers in Immunology : https://t.co/wOvPC5f7QB

🔍 Plus d’informations dans notre communiqué : https://t.co/7f4uRXo8lQ

[XENOTHERA @xenothera]

🔬 #LiverCancer | Recent #immunotherapy advancements offer hope for hepatocellular carcinoma (#HCC) patients.

Ongoing research aims to refine these treatments and improve patient outcomes 👇 @NewsMedical

https://t.co/nfxuOj75kf

[XENOTHERA @xenothera]

🔬#CancerResearch | @cityofhope's recent study published in @NatureMedicine highlights that CBM588, a live biotherapeutic product, can improve outcomes for metastatic kidney cancer patients when combined with #immunotherapy and tyrosine kinase inhibitors.

https://t.co/Agg9CZwgXd

[XENOTHERA @xenothera]

🧬 #Antibodies Market | A recent report by Research and Markets forecasts significant growth in the global research antibodies market, projecting it to reach $6.65 billion by 2029 👇

https://t.co/dZ5hhNeJJn

[XENOTHERA @xenothera]

🫀🫁 #Transplantation | Researchers at the Westmead Institute for Medical Research and the University of Sydney have identified universal molecular biomarkers for transplant rejection across all major organs using AI 👇 @medical_xpress

https://t.co/NyOXHERIw0

[XENOTHERA @xenothera]

🫁 #LungCancer #Treatment | Researchers at @BrighamWomens have developed a cutting-edge nanomedicine therapy that enhances the immune system's ability to target lung cancer cells.

Via @NewsMedical ⬇️
https://t.co/5PXWK2VYoj

[XENOTHERA @xenothera]

🇺🇸🔬 #ASCO2024 | A few takeaways from the @ASCO Annual Meeting on lung cancer, breast cancer, hepatocellular carcinoma, and melanoma. This confirms high unmet needs where XENOTHERA’s XON7 could bring strong benefits.

👉 More details in our press release: https://t.co/iSgi3zXMut

[XENOTHERA @xenothera]

🤖🔬@NIH #AI tool predicts #cancer patients’ #immunotherapy outcomes.

The model's efficacy was validated using data from 2,881 patients with 18 different types of solid tumours ⬇️

Vi @PharmaTechFocus https://t.co/lMaKDt4cP6